The relative magnitude of CV benefit of these drugs was recently debated in some network meta-analyses of randomized clinical trials, in which GLP-1 RA and SGLT2i showed similar efficacy in reducing atherosclerotic MACE and CV death, with trends towards more renal benefit and less hospitalization for heart failure with SGLT2i [166,167]. The gene discussed is GLP1R; the disease is heart failure.